{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:39:36Z","timestamp":1792690776750,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Spine Deform"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nusinersen provides functional benefits to Spinal Muscular Atrophy (SMA) patients but does not affect the prevalence or progression of scoliosis. This study aims to characterize perioperative curve characteristics and patient demographics among patients with SMA undergoing surgical treatment for early onset scoliosis (EOS) in a period spanning the introduction of nusinersen, a disease-modifying therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study utilized a multicenter international pediatric spinal deformity database. Patients with SMA undergoing initial surgical treatment for scoliosis between 1996 and 2023 were included. Patients were stratified by exposure to nusinersen preoperatively. Preoperative clinical,\u00a0radiographic characteristics, and first erect postoperative radiographic parameters were compared between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 210 patients were included, 37 with preoperative nusinersen exposure and 173 controls. Patients in the nusinersen group were younger at the time of intervention (6.5 vs. 7.6\u00a0years,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006) and had more spinal levels instrumented post-operatively (10.5 vs. 9.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033). Preoperative kyphosis (78\u00b0 vs. 67\u00b0,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027) and major curve magnitude (83\u00b0 vs. 75\u00b0,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030) were higher in the nusinersen group. Postoperative kyphosis was also greater in this group (48\u00b0 vs 42\u00b0,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042). There was no difference in postoperative major curve magnitude or percent correction. The nusinersen group was more commonly treated with magnetically controlled growing rods. A contemporaneous subgroup analysis (post-2017) showed that patients treated with nusinersen were younger at the time of surgery, although no significant differences in preoperative curve characteristics were noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nusinersen exposure was associated with younger age at surgery, greater curve magnitude, and increased kyphosis. These findings highlight potential changes in the phenotype of surgical candidates with EOS and SMA among patients treated with Nusinersen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43390-026-01359-1","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:52:41Z","timestamp":1789660361000},"page":"2297-2305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A changing early onset scoliosis phenotype in spinal muscular atrophy: nusinersen treatment is associated with younger age, increased curve magnitude, and kyphosis at the time of index surgery"],"prefix":"10.1007","volume":"14","author":[{"given":"Ian","family":"Hollyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talissa","family":"Generoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xochitl","family":"Bryson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleni","family":"Albarran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majella","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Mcintosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Ramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Roye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaysson","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"El-Hawary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pediatric Spine Study","family":"Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2526-4489","authenticated-orcid":false,"given":"John S","family":"Vorhies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"1","key":"1359_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1):155\u2013165","journal-title":"Cell"},{"issue":"6268","key":"1359_CR2","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/344767a0","volume":"344","author":"J Melki","year":"1990","unstructured":"Melki J, Abdelhak S, Sheth P, Bachelot M, Burlet P, Marcadet A, Aicardi J, Barois A, Carriere J, Fardeau M (1990) Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature 344(6268):767\u2013768","journal-title":"Nature"},{"key":"1359_CR3","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00415-017-8549-1","volume":"264","author":"IE Verhaart","year":"2017","unstructured":"Verhaart IE, Robertson A, Leary R, McMacken G, K\u00f6nig K, Kirschner J, Jones CC, Cook SF, Lochm\u00fcller H (2017) A multi-source approach to determine SMA incidence and research ready population. J Neurol 264:1465\u20131473","journal-title":"J Neurol"},{"issue":"5","key":"1359_CR4","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1542\/peds.2004-0668","volume":"114","author":"BH Chung","year":"2004","unstructured":"Chung BH, Wong VC, Ip P (2004) Spinal muscular atrophy: survival pattern and functional status. Pediatrics 114(5):e548\u2013e553","journal-title":"Pediatrics"},{"issue":"4","key":"1359_CR5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT (2015) Spinal muscular atrophy. Neurol Clin 33(4):831\u2013846","journal-title":"Neurol Clin"},{"key":"1359_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s43390-021-00302-w","volume":"9","author":"A Alhammoud","year":"2021","unstructured":"Alhammoud A, Othman Y, El-Hawary R, Mackenzie WG, Howard JJ (2021) The impact of scoliosis surgery on pulmonary function in spinal muscular atrophy: a systematic review. Spine Deformity 9:913\u2013921","journal-title":"Spine Deformity"},{"issue":"9","key":"1359_CR7","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1097\/BPO.0000000000002759","volume":"44","author":"S Ciftci","year":"2024","unstructured":"Ciftci S, Ulusaloglu AC, Shrader MW, Scavina MT, Mackenzie WG, Heinle R, Neal KM, Stall A, Howard JJ (2024) Scoliosis development in spinal muscular atrophy: the influences of genetic severity, functional level, and disease-modifying treatments. J Pediatr Orthop 44(9):e789\u2013e794","journal-title":"J Pediatr Orthop"},{"issue":"8","key":"1359_CR8","doi-asserted-by":"publisher","first-page":"E407","DOI":"10.1097\/BSD.0000000000000989","volume":"33","author":"P-C Shen","year":"2020","unstructured":"Shen P-C, Lu C-C, Liang W-C, Tien Y-C, Jong Y-J, Lu Y-M, Liu Z-M, Shih C-L, Chou S-H (2020) Predictors for deformity progression in a spinal muscular atrophy cohort after scoliosis correction surgery. Clinical Spine Surg 33(8):E407\u2013E414","journal-title":"Clinical Spine Surg"},{"issue":"16","key":"1359_CR9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1097\/BRS.0b013e3182194937","volume":"36","author":"MJ McElroy","year":"2011","unstructured":"McElroy MJ, Shaner AC, Crawford TO, Thompson GH, Kadakia RV, Akbarnia BA, Skaggs DL, Emans JB, Sponseller PD (2011) Growing rods for scoliosis in spinal muscular atrophy: structural effects, complications, and hospital stays. Spine 36(16):1305\u20131311","journal-title":"Spine"},{"key":"1359_CR10","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S214174","author":"HT Hjartarson","year":"2023","unstructured":"Hjartarson HT, Nathorst-B\u00f6\u00f6s K, Sejersen T (2023) Disease modifying therapies for the management of children with spinal muscular atrophy (5q SMA): an update on the emerging evidence. Drug design, develop ther. https:\/\/doi.org\/10.2147\/DDDT.S214174","journal-title":"Drug design, develop ther"},{"key":"1359_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-024-02051-2","volume":"84","author":"S Ramdas","year":"2024","unstructured":"Ramdas S, Oskoui M, Servais L (2024) Treatment options in spinal muscular atrophy: a pragmatic approach for clinicians. Drugs 84:747\u2013762","journal-title":"Drugs"},{"issue":"1","key":"1359_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dmcn.14027","volume":"61","author":"T Gidaro","year":"2019","unstructured":"Gidaro T, Servais L (2019) Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol 61(1):19\u201324","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"1359_CR13","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1097\/BPO.0000000000002595","volume":"44","author":"AC Ulusaloglu","year":"2024","unstructured":"Ulusaloglu AC, Asma A, Shrader MW, Scavina MT, Mackenzie WG, Erb A, Howard JJ (2024) Hip displacement in spinal muscular atrophy: the influences of genetic severity, functional level, and disease-modifying treatments. J Pediatr Orthop 44(3):e226\u2013e231","journal-title":"J Pediatr Orthop"},{"key":"1359_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.650532","volume":"12","author":"B Elsheikh","year":"2021","unstructured":"Elsheikh B, Severyn S, Zhao S, Kline D, Linsenmayer M, Kelly K, Tellez M, Bartlett A, Heintzman S, Reynolds J (2021) Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy. Front Neurol 12:650532","journal-title":"Front Neurol"},{"key":"1359_CR15","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","volume":"267","author":"A Osmanovic","year":"2020","unstructured":"Osmanovic A, Ranxha G, Kumpe M, M\u00fcschen L, Binz C, Wiehler F, Paracka L, K\u00f6rner S, Kollewe K, Petri S (2020) Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. J Neurol 267:2398\u20132407","journal-title":"J Neurol"},{"issue":"11","key":"1359_CR16","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, Grandis M, Trojsi F, Cerri F, Ferraro M (2020) Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 91(11):1166\u20131174","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1359_CR17","first-page":"194","volume":"24","author":"EE Neil","year":"2019","unstructured":"Neil EE, Bisaccia EK (2019) Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther 24(3):194\u2013203","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"1359_CR18","first-page":"e317","volume":"11","author":"T Duong","year":"2021","unstructured":"Duong T, Wolford C, McDermott MP, Macpherson CE, Pasternak A, Glanzman AM, Martens WB, Kichula E, Darras BT, De Vivo DC, Zolkipli-Cunningham Z (2021) Nusinersen treatment in adults with spinal muscular atrophy. Neurol: Clin Pract 11(3):e317\u2013e327","journal-title":"Neurol: Clin Pract"},{"issue":"12","key":"1359_CR19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","volume":"35","author":"SM Hoy","year":"2021","unstructured":"Hoy SM (2021) Nusinersen: a review in 5q spinal muscular atrophy. CNS Drugs 35(12):1317\u20131328","journal-title":"CNS Drugs"},{"issue":"4","key":"1359_CR20","first-page":"279","volume":"12","author":"F Al Amrani","year":"2022","unstructured":"Al Amrani F, Amin R, Chiang J, Xiao L, Boyd J, Law E, Nigro E, Weinstock L, Stosic A, Gonorazky HD (2022) Scoliosis in spinal muscular atrophy type 1 in the nusinersen era. Neurol: Clin Pract 12(4):279\u2013287","journal-title":"Neurol: Clin Pract"},{"issue":"2","key":"1359_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JND-230077","volume":"11","author":"HNH Ip","year":"2024","unstructured":"Ip HNH, Yu MKL, Wong WHS, Liu A, Kwan KYH, Chan SHS (2024) Treatment of symptomatic spinal muscular atrophy with nusinersen: a prospective longitudinal study on scoliosis progression. J Neuromuscul Dis 11(2):349\u2013359","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"1359_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s12519-022-00638-x","volume":"19","author":"HJ Shin","year":"2023","unstructured":"Shin HJ, Na J-H, Lee H, Lee Y-M (2023) Nusinersen for spinal muscular atrophy types II and III: a retrospective single-center study in South Korea. World J Pediatr 19(5):450\u2013459","journal-title":"World J Pediatr"},{"issue":"15","key":"1359_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12154901","volume":"12","author":"S Dunaway Young","year":"2023","unstructured":"Dunaway Young S, Montes J, Glanzman AM, Gee R, Day JW, Finkel RS, Darras BT, De Vivo DC, Gambino G, Foster R (2023) Nusinersen treatment of children with later-onset spinal muscular atrophy and scoliosis is associated with improvements or stabilization of motor function. J Clin Med 12(15):4901","journal-title":"J Clin Med"},{"issue":"3","key":"1359_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/18632521241235028","volume":"18","author":"NE Yasar","year":"2024","unstructured":"Yasar NE, Ozdemir G, Uzun Ata E, Ayvali MO, Ata N, Ulgu M, Dumlup\u0131nar E, Birinci S, Bingol I, Bekmez S (2024) Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: what about spine and hip? J Child Orthop 18(3):322\u2013330","journal-title":"J Child Orthop"},{"issue":"6","key":"1359_CR25","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/01241398-199011000-00007","volume":"10","author":"WJ Maloney","year":"1990","unstructured":"Maloney WJ, Rinsky LA, Gamble JG (1990) Simultaneous correction of pelvic obliquity, frontal plane, and sagittal plane deformities in neuromuscular scoliosis using a unit rod with segmental sublaminar wires: a preliminary report. J Pediatr Orthop 10(6):742\u2013749","journal-title":"J Pediatr Orthop"},{"issue":"21","key":"1359_CR26","doi-asserted-by":"publisher","first-page":"e2103","DOI":"10.1212\/WNL.0000000000207878","volume":"101","author":"V Aponte Ribero","year":"2023","unstructured":"Aponte Ribero V, Mart\u00ed Y, Batson S, Mitchell S, Gorni K, Gusset N, Oskoui M, Servais L, Sutherland CS (2023) Systematic literature review of the natural history of spinal muscular atrophy motor function, scoliosis, and contractures. Neurology 101(21):e2103\u2013e2113. https:\/\/doi.org\/10.1212\/WNL.0000000000207878","journal-title":"Neurology"},{"key":"1359_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","volume":"51","author":"D Giess","year":"2024","unstructured":"Giess D, Erdos J, Wild C (2024) An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies. Eur J Paediatr Neurol 51:84\u201392. https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.004. (Epub 2024 Jun 17. PMID: 38905882.)","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"1359_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/JND-200551","volume":"8","author":"RH Mendon\u00e7a","year":"2021","unstructured":"Mendon\u00e7a RH, Polido GJ, Matsui C Jr, Silva A, Solla DJ, Reed UC, Zanoteli E (2021) Real-world data from Nusinersen treatment for patients with later-onset spinal muscular atrophy: a single center experience. J Neuromuscul Dis 8(1):101\u2013108","journal-title":"J Neuromuscul Dis"},{"issue":"15","key":"1359_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241511939","volume":"24","author":"H Nishio","year":"2023","unstructured":"Nishio H, Niba ETE, Saito T, Okamoto K, Takeshima Y, Awano H (2023) Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci 24(15):11939","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1359_CR30","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.3390\/jcm12082839","volume":"12","author":"A Belan\u010di\u0107","year":"2023","unstructured":"Belan\u010di\u0107 A, Strbad T, Ku\u010dan \u0160tigli\u0107 M, Vitezi\u0107 D (2023) Effectiveness of Nusinersen in type 1, 2 and 3 spinal muscular atrophy: Croatian real-world data. J Clin Med 12(8):2839","journal-title":"J Clin Med"}],"container-title":["Spine Deformity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43390-026-01359-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43390-026-01359-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43390-026-01359-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:42:07Z","timestamp":1792687327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43390-026-01359-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s43390-026-01359-1","relation":{},"ISSN":["2212-134X","2212-1358"],"issn-type":[{"value":"2212-134X","type":"print"},{"value":"2212-1358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. John Vorhies receives grant funding from the Scoliosis Research Society (SRS), Pediatric Orthopaedic Surgery of North America (POSNA), and Stanford University. Dr. John Vorhies is a consultant for NView, NSite Medical, Orthopediatrics.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Stanford University (IRB No. 61425).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}